

uniQure N.V. (QURE)


Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001590560

uniQure N.V. QURE; healthcare					
Grade	D	A B C D E	fourth fifth of 371 graded peers percentile 70.8; sampling error 2.5 points; lower is stronger		
Rank	263 of 371				
Profitability	D		percentile 73.3		
Solvency	B		percentile 29.7		
Growth and financing	D		percentile 63.9		
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025				
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	\$591M to \$2.67B assets total assets \$824.9M				
Standard universe	inside revenue above \$1M and assets above \$10M				
Warnings	none active; fortress balance sheet not computable: distress				
Inputs computable	8 of 14				
Graded from	filings received through Mar 2, 2026 221 days before the rescans; latest periodic filing 10-Q received Jul 29, 2026				
Last close	\$22.52 2026-10-08; market equity \$1.4B				
Price used in grade	None				



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C/D from Mar 21, 2023, C from Apr 21, 2023, D from Mar 21,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington's disease, refractory mesial temporal lobe epilepsy ("MTLE"), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 ("SOD1-ALS"). In September 2025, we announced

positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 73.3						
Gross profitability		1.7%	32.2%	89.5	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(3.0%)	(6.6%)	71.2	811	2025-12-31
Gross margin stability, five years		3.6 pts	2.8 pts	59.1	243	2025-12-31
Solvency, sleeve percentile 29.7						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(1.71)	(0.31)	44.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		10.43x	2.96x	15.4	839	2025-12-31
Growth and financing, sleeve percentile 63.9						
Revenue growth, three-year compound		(46.7%)	10.0%	95.4	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		5.4%	2.1%	39.7	704	2025-12-31
Net share issuance, one year		15.6%	2.5%	56.7	634	2026-02-26


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 8,318,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
258	Iovance Biotherapeutics, Inc. (IOVA)	69.5	D	dilution, short runway
259	Scienture Holdings, Inc. (SCNX)	69.7	D	fortress balance sheet
260	Rockwell Medical, Inc. (RMTI)	70.0	D	
261	Bioventus Inc. (BVS)	70.3	D	
262	Ovid Therapeutics Inc. (OVID)	70.5	D	dilution, short runway
263	uniQure N.V. (QURE) <	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN)	71.1	D	
265	AbCellera Biologics Inc. (ABCL)	71.4	D	
266	Cumberland Pharmaceuticals Inc. (CPIX)	71.6	D	
267	Bausch & Lomb Corp. (BLCO)	71.9	D	
268	Pennant Group, Inc. (PNTG)	72.2	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.6%)	8.0%	33
Distance from 52-week high	(68.1%)	(31.4%)	12
EBIT to enterprise value	(13.7%)	(1.5%)	28
Free cash flow yield	(12.5%)	(1.0%)	29
Book value to price	0.11	0.28	26
Sales to price	0.01	0.31	7
Composite equity issuance, five years	33.8%	20.3%	60
Relative strength against the sector, log excess return	(0.39)	(0.14)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$140.0M
Operating cash flow, four quarters	-\$172.1M
Months of runway	9.8
Days since last periodic filing	72 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	\$50.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$16.1M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.7M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
3	assets	us-gaap:Assets	\$824.9M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
4	operating income	us-gaap:OperatingIncomeLoss	-\$185.3M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNondeductible	\$183.0M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$5.6M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
7	total debt	us-gaap:LongTermDebt	\$71.9M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
8	book equity	us-gaap:StockholdersEquity	\$198.9M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$80.2M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
10	total debt	us-gaap:LongTermDebt	\$66.0M	2024-12-31	2025-02-27	10-K	0001558370-25-001699
11	book equity	us-gaap:StockholdersEquity	-\$6.8M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$158.9M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
13	net income	us-gaap:NetIncomeLoss	-\$199.0M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$178.0M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
15	assets	us-gaap:Assets	\$556.5M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
16	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$27.1M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.3M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
18	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$15.8M	2023-12-31	2026-03-02	10-K	0001104659-26-021898
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$65,000	2023-12-31	2026-03-02	10-K	0001104659-26-021898
20	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$106.5M	2022-12-31	2025-02-27	10-K	0001558370-25-001699
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.3M	2022-12-31	2025-02-27	10-K	0001558370-25-001699
22	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$524.0M	2021-12-31	2024-02-28	10-K	0001558370-24-001915
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$25.0M	2021-12-31	2024-02-28	10-K	0001558370-24-001915
24	current assets	us-gaap:AssetsCurrent	\$656.0M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
25	current liabilities	us-gaap:LiabilitiesCurrent	\$62.9M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.3B	2025-12-31	2026-03-02	10-K	0001104659-26-021898
27	liabilities	us-gaap:Liabilities	\$626.0M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
28	depreciation amortization	us-gaap:Depreciation	\$9.1M	2025-12-31	2026-03-02	10-K	0001104659-26-021898
29	operating income	us-gaap:OperatingIncomeLoss	-\$282.9M	2023-12-31	2026-03-02	10-K	0001104659-26-021898
30	interest expense	us-gaap:InterestExpense	\$41.6M	2023-12-31	2024-02-28	10-K	0001558370-24-001915
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$439,000	2025-12-31	2026-03-02	10-K	0001104659-26-021898
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$182.7M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.4M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$145.9M	2023-12-31	2026-03-02	10-K	0001104659-26-021898
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.2M	2023-12-31	2026-03-02	10-K	0001104659-26-021898
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$145.1M	2022-12-31	2025-02-27	10-K	0001558370-25-001699
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$17.7M	2022-12-31	2025-02-27	10-K	0001558370-25-001699
38	current assets	us-gaap:AssetsCurrent	\$390.3M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
39	current liabilities	us-gaap:LiabilitiesCurrent	\$40.1M	2024-12-31	2026-03-02	10-K	0001104659-26-021898
40	assets	us-gaap:Assets	\$831.7M	2023-12-31	2025-02-27	10-K	0001558370-25-001699
41	assets	us-gaap:Assets	\$705.0M	2022-12-31	2024-02-28	10-K	0001558370-24-001915
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	62,529,408	2026-02-26	2026-03-02	10-K	0001104659-26-021898
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	54,076,880	2025-02-24	2025-02-27	10-K	0001558370-25-001699